|
Date first patient entered: TBA
Target Accrual: 699
Aim: A randomized study to demonstrate a difference in progression-free survival (PFS) for primary treatment with temozolomide in order to assess: whether PFS and OS can be prolonged by primary chemotherapy with temozolomide, whether the incidence of late toxicity can be decreased by using primary chemotherapy, the toxicity profile of the two treatments and the quality of life of the patients The impact of 1p deletions in low-grade gliomas: prognostic effect of tumors with deletion on PFS overall and by treatment group. Benefit for patients with LGGs and deletions treated with TMZ compared to radiotherapy alone with respect to survival. Interaction between treatment and cytogenetic features.
TROG Trial Chairperson
Dr Gail Ryan
Division of Radiation Oncology
Peter MacCallum Cancer Centre
Tel: +61 3 9656 1111 Fax: +61 3 9656 1424
Trial Centre Data Manager
Dr Juliana Di lulio
Statistical Centre
Peter MacCallum Cancer Centre
St Andrews Place, East Melbourne VIC 3002
Tel: +61 3 9656 3786 Fax: +61 3 9656 1420
More Information
[ Open
Trials - Home ]
|
